SAN DIEGO, CA--(Marketwired - Dec 3, 2013) - NuVasive, Inc. (
NuVasive will exhibit and demonstrate the Company's game-changing products and procedures, including XLIF®, Precept®, Armada®, MAS® TLIF, Biologics, and the NVM5® neuromonitoring system.
"We are very excited to showcase our innovative procedural solutions at the German Spine Society Meeting," said Paul Kosters, NuVasive Senior Vice President of Europe, Middle East, and Africa. "Our flagship procedure, XLIF, will be showcased during a lunch workshop and keynote address led by Dr. Luiz Pimenta, a world-renowned expert in minimally disruptive spine surgery and motion preservation. The well-attended meeting offers an exceptional platform to educate the world's leading surgeons and healthcare professionals on our comprehensive portfolio of unique products and procedures."
The German Spine Society Meeting is a widely attended event, where more than one thousand spine care professionals meet to exchange ideas, gain additional training, and learn about the latest advancements in techniques and technologies. This year, more than 100 presentations and scientific posters will be presented.
NuVasive® is scheduled to participate in the following events at the German Spine Society Meeting:
- NuVasive Technical Exhibit, Stand Number 31: The NuVasive technical exhibit booth will feature a number of innovative, minimally disruptive products and procedures, including: XLIF®, Precept®, Armanda®, MAS® TLIF, Biologics, and the NVM5® neuromonitoring system.
- NuVasive Keynote Speech: Dr. Luiz Pimenta will lead a keynote speech on XLIF from 17:10 to 17:40 GMT on Thursday, December 5th.
- NuVasive Lunch Workshop: NuVasive, along with surgeon proctors Dr. Luiz Pimenta, Brazil; Dr. Markus Quante, Germany; and Dr. Volkmar Heidecke, Germany; will host a hands-on workshop on Friday, December 6, 2013 from 13:00-14:30 GMT in Spektrum 1. The workshop is titled, "Advanced Applications of eXtreme Lateral Interbody Fusion (XLIF) and Percutaneous Fixation."
For more information about the 8th Annual Meeting of the German Spine Society, please visit: http://www.dwg-kongress.de/
About the 8th Annual Meeting of the German Spine Society:
The German Spine Society was founded in 2006 as a union of the former German Society for Spine Surgery and the Society for Spinal Research. Since the unification, the membership has rapidly grown. With more than 700 members presently, the German Spine Society is now the largest spine society in Europe.
NuVasive is an innovative global medical device company that is changing spine surgery with minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the 4th largest player in the $8.2 billion global spine market.
NuVasive offers a comprehensive spine portfolio of over 80 unique products developed to improve spine surgery and patient outcomes. The Company's principal procedural solution is its Maximum Access Surgery, or MAS® platform for lateral spine fusion. MAS provides safe, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.
Having pioneered the lateral approach to spine fusion, NuVasive continues to be at the forefront of the spine industry's shift toward less invasive solutions. The Company's dedication to innovation continues to spawn game changing technology such as the PCM® motion preserving disc for the cervical spine, XLIF® Corpectomy for tumor and trauma, and Armada®, which treats adult degenerative scoliosis in a less invasive fashion. The Company has also developed procedural solutions that completely redefine and improve upon traditional procedures like TLIF, PLIF, Posterior Fixation, and ALIF. NuVasive's solutions are increasingly being adopted internationally, as the Company lays the groundwork to continue growing as a global business and to offer industry-leading, Absolutely Responsive customer service to surgeons world-wide. NuVasive is focused on becoming a $1 Billion Start-Up™; taking market share by maintaining a commitment to Superior Clinical Outcomes, Speed of Innovation®, and Absolute Responsiveness®.
NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties are described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.